Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data

Author:

Ailawadhi Sikander1,Romanus Dorothy2,Shah Surbhi3,Fraeman Kathy3,Saragoussi Delphine4,Buus Rebecca Morris5,Nguyen Binh6,Cherepanov Dasha2,Lamerato Lois7ORCID,Berger Ariel3ORCID

Affiliation:

1. Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA

2. Global Evidence & Outcomes, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA

3. Real-World Evidence, Evidera/PPD (part of Thermo fisher Scientific), Bethesda, MD 20814, USA

4. Real-World Evidence, Evidera/PPD (part of Thermo fisher Scientific), London, W6 8BJ, UK

5. Epidemiology and Scientific Affairs, Clinical Development Services Division, Evidera/PPD (part of Thermo Fisher Scientific), Bethesda, MD 20814, USA

6. Medical Science and Strategy, Oncology, PPD (part of Thermo Fisher Scientific), Bethesda, MD 20814, USA

7. Henry Ford Health, Detroit, MI 48202, USA

Abstract

Aim: To validate algorithms based on electronic health data to identify composition of lines of therapy (LOT) in multiple myeloma (MM). Materials & methods: This study used available electronic health data for selected adults within Henry Ford Health (Michigan, USA) newly diagnosed with MM in 2006–2017. Algorithm performance in this population was verified via chart review. As with prior oncology studies, good performance was defined as positive predictive value (PPV) ≥75%. Results: Accuracy for identifying LOT1 (N = 133) was 85.0%. For the most frequent regimens, accuracy was 92.5–97.7%, PPV 80.6–93.8%, sensitivity 88.2–89.3% and specificity 94.3–99.1%. Algorithm performance decreased in subsequent LOTs, with decreasing sample sizes. Only 19.5% of patients received maintenance therapy during LOT1. Accuracy for identifying maintenance therapy was 85.7%; PPV for the most common maintenance therapy was 73.3%. Conclusion: Algorithms performed well in identifying LOT1 – especially more commonly used regimens – and slightly less well in identifying maintenance therapy therein.

Funder

Takeda Pharmaceutical Company

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Reference34 articles.

1. National Comprehensive Cancer Network. NCCN Guidelines: Multiple Myeloma, Version 1.2024 (2023). www.nccn.org/guidelines/guidelines-detail?category=1&id=1445

2. Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies

3. Targeted Therapies for Multiple Myeloma

4. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3